MNG1204
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.483
- E2F_TARGETS+0.413
- G2M_CHECKPOINT+0.397
- MYC_TARGETS_V1+0.339
- TGF_BETA_SIGNALING+0.229
- ANDROGEN_RESPONSE+0.177
- HEME_METABOLISM+0.170
- SPERMATOGENESIS+0.154
- MITOTIC_SPINDLE+0.153
- MYC_TARGETS_V2+0.137
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.343
- ANGIOGENESIS-0.337
- MYOGENESIS-0.323
- TNFA_SIGNALING_VIA_NFKB-0.306
- COAGULATION-0.290
- HYPOXIA-0.264
- APICAL_JUNCTION-0.254
- ALLOGRAFT_REJECTION-0.253
- COMPLEMENT-0.242
- P53_PATHWAY-0.237
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A1FW-01A-11R-A13Q-07 | — | B | 0.856 |
| 2 | TCGA-C8-A1HK-01A-21R-A13Q-07 | — | C | 0.843 |
| 3 | TCGA-AO-A1KS-01A-11R-A13Q-07 | — | B | 0.834 |
| 4 | BS_7G42J2SK | EPN | Supratentorial EPN | 0.817 |
| 5 | MDT-AP-3307 | Med | Medulloblastoma | 0.817 |
| 6 | R144 | — | — | 0.813 |
| 7 | E79FE058-F03E-45F3-A939-356B0427E1B7 | — | — | 0.812 |
| 8 | TCGA-AR-A0U3-01A-11R-A109-07 | — | B | 0.812 |
| 9 | MDT-AP-3288 | Med | Medulloblastoma | 0.811 |
| 10 | 65567450-e04a-4251-9939-8d2545077236 | — | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.483 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.413 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.397 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.339 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.229 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.177 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.154 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.153 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.137 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.133 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.128 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.122 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.113 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.112 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.111 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.086 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.077 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.052 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.045 | Inavolisib | — uncovered |